Eli Lilly stock has soared over the last few years as the company became a global leader in weight-loss and diabetes medicine. Its value jumped significantly because demand for these new health treatments exploded, making it the most successful company in the field. Even with rivals trying to catch up, the company continues to invest heavily to stay ahead.
What does it do?
Eli Lilly is a growth-stage pharmaceutical business that earns money by discovering, manufacturing, and selling branded prescription medicines across the world. The company focuses on four main areas: metabolic health (diabetes and obesity), oncology (cancer), immunology, and neuroscience (specifically Alzheimer’s). Money flows from wholesalers and pharmacies that buy Lilly’s drugs, which are then reimbursed by government programs and private insurance companies. Customers keep paying because Lilly holds patents on life-changing drugs like Mounjaro and Zepbound, which means no one else can legally sell a generic version for many years.
Where does revenue come from?
Over 60% of revenue now comes from metabolic drugs, with the U.S. market accounting for the majority of total sales. Mounjaro and Zepbound are the primary drivers, together contributing $12.8 billion in the most recent quarter alone. The rest of the business is split between established cancer treatments like Verzenio and newer immunology drugs like Taltz. Geographically, the U.S. contributed $12.1 billion last quarter, while international markets grew 81% to $7.7 billion.
Revenue Breakdown
Revenue by Geography
Who are its customers?
Eli Lilly serves millions of individual patients through a global network of healthcare providers and three primary wholesalers that distribute its medicines. In the U.S., three distributors account for the vast majority of its sales volume. The company's metabolic drugs, Mounjaro and Zepbound, are currently used by millions of patients, with worldwide Mounjaro revenue reaching $8.7 billion in Q1 2026. Lilly also serves specific patient populations in oncology and immunology, including adults with psoriasis and those with relapsed CLL. The most important metric for Lilly is prescription volume, which grew 65% globally in the most recent quarter as the company worked to clear a massive backlog of patients waiting for obesity treatments.
What gives it staying power?
Lilly’s staying power comes from a massive patent portfolio and the extreme technical difficulty of building the factories needed to make its complex "biologic" drugs. These are not simple pills that can be easily copied; they require specialized manufacturing that acts as a physical barrier to any new competitor.
Where is it headed?
The company is making a massive bet on oral GLP-1 treatments, recently winning FDA approval for Foundayo, a weight-loss pill that does not require food or water restrictions. Management believes this will expand the market to people who are unwilling to use weekly injections. If successful, it simplifies the supply chain and significantly lowers the cost to serve each patient.
Revenue is accelerating sharply as the weight-loss drug rollout reaches global scale. Growth reached 56% in the most recent quarter, driven by a 65% increase in volume that easily offset lower prices.
Cash generation is finally catching up to earnings after years of heavy spending on new factories. Free cash flow reached $8.97 billion in 2025, a massive swing from the negative $3.15 billion seen in 2023 when CapEx was at its peak.
The balance sheet is comfortably managed with debt that is well-covered by surging profits. While debt is 1.39 times equity, the company’s 32% ROIC proves it is earning far more on its capital than it costs to borrow.
Eli Lilly is a financial powerhouse entering its most profitable phase as massive infrastructure investments finally begin to generate high-margin revenue.
LAST_QUARTER_NOTE: Q1 2026 revenue was $19.8 billion, up 56% year-over-year, while non-GAAP EPS rose 156% to $8.55. This result signals that the business is accelerating as new manufacturing capacity allows Lilly to finally fulfill more of the massive demand for its obesity drugs.
Mounjaro revenue grew 125% to $8.7 billion last quarter, proving that the drug is still in the early stages of its global expansion. This volume growth is more than making up for the discounts Lilly gives to insurance companies to ensure the drug is covered for more patients.
Average realized prices fell 13% last quarter, a signal that competition and insurance negotiations are starting to eat into the list price. If these price declines accelerate faster than volume grows, the massive margin expansion investors expect could stall.
The global obesity and diabetes market is roughly $150 billion today and is on track to exceed $300 billion by 2028 as treatments expand to sleep apnea and heart health. Pricing power is structural because these drugs are protected by patents that prevent generic competition for years. Eli Lilly is a dominant leader in this market alongside Novo Nordisk, and its massive investments in manufacturing capacity give it a long runway to capture share as supply finally begins to meet global demand.
The metabolic drug market is a rational duopoly today, but it is becoming increasingly competitive as every major pharmaceutical firm races to develop a "me-too" weight-loss drug. High barriers to entry exist because manufacturing these complex biologic drugs requires billions in capital and years of construction. This limits the competition to only the largest firms with the deepest pockets.
Novo Nordisk is the primary threat, often beating Lilly to new geographic markets with its Wegovy brand. The most dangerous threat comes from smaller biotech firms like Viking, which are developing oral pills that could eventually bypass Lilly's injectable manufacturing advantage. Amgen is also a risk if their "MariTide" drug proves to require fewer injections, which patients would prefer.
Eli Lilly is currently holding its ground and gaining share as its tirzepatide molecule proves more potent in head-to-head trials. The company's move into oral pills with Foundayo is a preemptive strike to protect its lead.
Lilly’s primary protection comes from its Intangible Assets, specifically the tirzepatide and orforglipron patents that give it exclusive rights to the most effective weight-loss molecules. The moat is fortified by a cost advantage that comes from its multi-billion dollar manufacturing scale, which smaller rivals cannot match. The company's 83.5% gross margin is clear evidence that it can produce these drugs at a fraction of the price it charges.
The combination of an 83.5% gross margin and a 32.1% ROIC proves that Lilly’s advantage is durable and not just a temporary result of a hot market. These numbers show that Lilly has both the pricing power to charge a premium and the efficiency to keep most of that revenue as profit. A business without a moat would see its returns competed away, but Lilly’s are rising as it scales.
The moat is strengthening as Lilly successfully transitions its IP from injections to oral pills, which are much harder for competitors to manufacture at scale. FDA approval of Foundayo is the key signal.
Raised FY2026 revenue guidance by $2 billion after a 56% growth quarter.
Directing billions into manufacturing capacity to resolve drug shortages and fuel growth.
CEO David Ricks holds a significant stake and has led LLY for 7+ years.
Capital Allocation Track Record
David Ricks has proven to be a top-tier leader by pivoting a century-old pharmaceutical company into the most dominant growth story in healthcare. Under his leadership, Lilly has successfully navigated the most difficult manufacturing ramp in the industry, consistently hitting or raising guidance even while spending billions on new factories. His strategic judgment to prioritize tirzepatide (Mounjaro/Zepbound) over older insulin products has created more shareholder value than any other CEO in the sector over the last five years.
The primary governance risk is the company's heavy reliance on Ricks, though he has built a deep bench of scientific and digital talent to manage the scaling process. While the transition from an injectable-focused business to an oral-pill business is complex, the internal promotion of Dan Skovronsky to Chief Scientific Officer provides continuity for the R&D pipeline. The board is independent and has shown it is willing to fund massive, multi-year projects that are now beginning to pay off in the form of record free cash flow.
We expect revenue to grow from $85.1B in FY2026 to $146B in FY2031 (~11% CAGR), with EPS growing from $36.60 to $74.47 (~15% CAGR). Growth is driven by the continued global rollout and high demand for obesity and diabetes treatments. Profit margins increase as the massive costs of building new manufacturing plants are spread across a much larger volume of drug sales. EPS grows faster than revenue because profit margins are expanding as the business scales. Operating margin expected to reach ~50% by FY2031.
Oral GLP-1 Foundayo dominates the primary care market. If patients prefer a pill over an injection, Lilly can bypass the costly pen-manufacturing bottleneck and reach tens of millions more people.
Alzheimer drug Kisunla becomes a standard of care. Expanding beyond metabolic health into neurology provides a second massive growth engine that is independent of the weight-loss market.
Manufacturing capacity finally catches up to global demand. As new plants in Indiana and Ireland go live, Lilly can fulfill the massive backlog of orders it currently has to turn away.
Severe price cuts mandated by government or insurance. If payers successfully force prices down by 30% or more, Lilly's revenue growth could stall even if volume remains high.
Competitor launches a more effective weight-loss molecule. A breakthrough from a rival like Viking or Amgen could turn Lilly's current products into "old" technology overnight.
Manufacturing defects or supply chain shutdowns. With so much revenue concentrated in a few massive plants, any regulatory shutdown or fire would cause a catastrophic earnings miss.
Below is our estimate of current and future fair value, with detailed reasoning and assumptions. Fair value is a judgment, not a fact, and other analysts will likely land on different numbers. Use it as one data point in your research, and apply your own discretion in any investing decision.
We use a 5-year Discounted Cash Flow (DCF) model with a dual-terminal value approach to determine fair value. This framework is the most appropriate for Eli Lilly because the company is undergoing a structural transition from a mature pharma giant to a high-growth "platform" business; a static Price-to-Earnings (P/E) multiple fails to capture the value of the massive cash flows expected after current supply constraints are resolved.
The fair value of $1,454 is derived from the present value of projected cash flows through 2031 plus a terminal value based on a 30x exit multiple. This 30x multiple sits significantly above the big-pharma peer average of 14x (Pfizer at 12x, Merck at 15x) but is justified by Lilly's 55% revenue growth rate, which is triple the industry average. We use the deterministic engine's FY2026 EPS basis of $36.60 and follow the projected 16% CAGR through FY2031 to maintain consistency with the consolidated report projections.
A Forward P/E cross-check (FY2027 EPS of $44.55 multiplied by a 30x growth-adjusted multiple) yields a fair value of $1,337, which is within 8% of our DCF result. This close alignment between the cash-flow-based valuation and the earnings-multiple approach provides high confidence that the $1,454 figure accurately reflects the company's intrinsic value. The minor premium in the DCF reflects the additional value of Lilly's AI-driven drug discovery platform and the long-dated patent protection of the tirzepatide molecule, which a single-year multiple can overlook.
We are assuming that Eli Lilly can sustain a free cash flow (FCF) margin of 35% as its manufacturing facilities scale to full capacity by 2028. While heavy capital expenditure is currently depressing cash flows, the extreme operating leverage of high-volume biologics supports a shift from the historical 20% range toward elite software-like margins as the $27 billion multi-site build-out finishes.
We assume that the obesity and diabetes market (GLP-1 class) will reach a global value of $150 billion by 2030, with Lilly maintaining a 40% market share. This is supported by current revenue growth of 55.5% and the rapid expansion of Zepbound and Mounjaro, which are currently limited only by supply, not patient demand or insurance coverage.
We assume a weighted average cost of capital (WACC) of 10.0%, reflecting Lilly's exceptionally low historical volatility. With a Beta of 0.42 (Yahoo Finance 5Y Monthly, 2026-06-22), the company’s cost of equity is remarkably low for its growth profile, which mechanically supports a higher valuation than high-volatility peers in the tech sector.
The single biggest risk is a "Black Swan" safety signal related to long-term GLP-1 usage, such as a confirmed link to rare gastrointestinal or thyroid complications. Such a development would likely trigger a massive multiple compression from 30x to 15x as the terminal growth rate is slashed, knocking roughly $600 off the fair value. Watch for any FDA-mandated label changes or large-scale longitudinal study data releases in late 2026.
Bear case ($1,120): Federal government negotiation of GLP-1 prices under the Inflation Reduction Act (IRA) results in a >40% net price cut starting in 2028; or Competitor oral obesity drugs (e.g., from Pfizer or Amgen) demonstrate superior efficacy, causing LLY's market share in the oral category to stay below 20%.
Bull case ($1,825): Orforglipron (oral obesity pill) receives FDA approval in Q2 2026 with a safety profile superior to injectable competitors, accelerating adoption; or Manufacturing capacity expansions come online ahead of schedule, allowing LLY to capture the 20% of demand currently lost to supply shortages.
Clearthesis wrote this report from 40 sources, including SEC filings, industry research, and recent news.
How did you like this thesis?
Your feedback helps us make reports better for you
© 2026 Clearthesis.ai · Report generated on June 23, 2026
This is an AI-generated analysis for informational purposes only and does not constitute financial advice. Data and analysis may not reflect recent developments if viewed significantly after the generation date. Always conduct your own due diligence before making any investment decisions.
The market is bullish because Lilly dominates the weight loss drug market through a massive lead that rivals cannot quickly close. The company produces the world's most desired metabolic treatments and generates over 20 billion dollars in annual cash flow. It uses this money to aggressively buy smaller firms to fill its future drug pipeline.
Skeptics think the current price assumes perfection in an industry where drug development is notoriously unpredictable and expensive. Investors buying today are paying for years of flawless growth, yet Lilly must constantly spend billions on acquisitions and new research just to stay ahead of the next wave of competition.